Benutzerspezifische Werkzeuge

Publikationen - 2004

Grutzmann,R., Pilarsky,C., Ammerpohl,O., Luttges,J., Bohme,A., Sipos,B., Foerder,M., Alldinger,I., Jahnke,B., Schackert,H.K., Kalthoff,H., Kremer,B., Kloppel,G., and Saeger,H.D. (2004). Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. Neoplasia. 6, 611-622.
Plaschke,J., Engel,C., Kruger,S., Holinski-Feder,E., Pagenstecher,C., Mangold,E., Moeslein,G., Schulmann,K., Gebert,J., von Knebel,D.M., Ruschoff,J., Loeffler,M., and Schackert,H.K. (2004). Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium. J. Clin. Oncol. 22, 4486-4494.
Fitze,G., Saeger,H.D., Roesner,D., and Schackert,H.K. (2004). [Management of multiple endocrine neoplasia syndrome type 2 families in association with rare germline mutations of the RET proto-oncogene]. Klin. Padiatr. 216, 270-276.
Kruger,S., Bier,A., Plaschke,J., Hohl,R., Aust,D.E., Kreuz,F.R., Pistorius,S.R., Saeger,H.D., Rothhammer,V., Al Taie,O., and Schackert,H.K. (2004). Ten novel MSH2 and MLH1 germline mutations in families with HNPCC. Hum. Mutat. 24, 351-352.
Habermann,B., Bebin,A.G., Herklotz,S., Volkmer,M., Eckelt,K., Pehlke,K., Epperlein,H.H., Schackert,H.K., Wiebe,G., and Tanaka,E.M. (2004). An Ambystoma mexicanum EST sequencing project: analysis of 17,352 expressed sequence tags from embryonic and regenerating blastema cDNA libraries. Genome Biol. 5, R67.
Martinez,R., Schackert,H.K., Plaschke,J., Baretton,G., Appelt,H., and Schackert,G. (2004). Molecular mechanisms associated with chromosomal and microsatellite instability in sporadic glioblastoma multiforme. Oncology 66, 395-403.
Fitze,G., Schreiber,M., Hohenberger,W., Hummer,H.P., Roesner,D., and Schackert,H.K. (2004). Interaction of RET proto-oncogene codon 609 germline mutations with RET haplotypes characterized by c.135G>A alleles modifying MEN 2A or HSCR phenotypes. Am. J. Med. Genet. A 129A, 323-325.
Gorgens,H., Fitze,G., Roesner,D., and Schackert,H.K. (2004). One-step analysis of ten functional haplotype combinations of the basic RET promoter with a LightCycler assay. Clin. Chem. 50, 1693-1695.
Krex,D., Konig,I.R., Ziegler,A., Schackert,H.K., and Schackert,G. (2004). Extended single nucleotide polymorphism and haplotype analysis of the elastin gene in Caucasians with intracranial aneurysms provides evidence for racially/ethnically based differences. Cerebrovasc. Dis. 18, 104-110.
Krex,D., Kotteck,K., Konig,I.R., Ziegler,A., Schackert,H.K., and Schackert,G. (2004). Matrix metalloproteinase-9 coding sequence single-nucleotide polymorphisms in caucasians with intracranial aneurysms. Neurosurgery 55, 207-212.
Noack,B., Gorgens,H., Hoffmann,T., Fanghanel,J., Kocher,T., Eickholz,P., and Schackert,H.K. (2004). Novel mutations in the cathepsin C gene in patients with pre-pubertal aggressive periodontitis and Papillon-Lefevre syndrome. J. Dent. Res. 83, 368-370.
Koy,S., Hauses,M., Appelt,H., Friedrich,K., Schackert,H.K., and Eckelt,U. (2004). Loss of expression of ZAC/LOT1 in squamous cell carcinomas of head and neck. Head Neck 26, 338-344.
Hampl,J.A., Hampl,M., Reiss,G., Koch,R., Saeger,H.D., and Schackert,H.K. (2004). Loss of BRCA2 correlates with reduced long-term survival of sporadic breast cancer patients. Anticancer Res. 24, 281-290.
Grutzmann,R., Luttges,J., Sipos,B., Ammerpohl,O., Dobrowolski,F., Alldinger,I., Kersting,S., Ockert,D., Koch,R., Kalthoff,H., Schackert,H.K., Saeger,H.D., Kloppel,G., and Pilarsky,C. (2004). ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br. J. Cancer 90, 1053-1058.
Plaschke,J., Kruger,S., Dietmaier,W., Gebert,J., Sutter,C., Mangold,E., Pagenstecher,C., Holinski-Feder,E., Schulmann,K., Moslein,G., Ruschoff,J., Engel,C., Evans,G., and Schackert,H.K. (2004). Eight novel MSH6 germline mutations in patients with familial and nonfamilial colorectal cancer selected by loss of protein expression in tumor tissue. Hum. Mutat. 23, 285.
Plaschke,J., Kruger,S., Jeske,B., Theissig,F., Kreuz,F.R., Pistorius,S., Saeger,H.D., Iaccarino,I., Marra,G., and Schackert,H.K. (2004). Loss of MSH3 protein expression is frequent in MLH1-deficient colorectal cancer and is associated with disease progression. Cancer Res. 64, 864-870.
Grutzmann,R., Saeger,H.D., Luttges,J., Schackert,H.K., Kalthoff,H., Kloppel,G., and Pilarsky,C. (2004). Microarray-based gene expression profiling in pancreatic ductal carcinoma: status quo and perspectives. Int. J. Colorectal Dis. 19, 401-413.